Download PDF
Exp Clin Endocrinol Diabetes 2005; 113(4): 208-213
DOI: 10.1055/s-2005-837652
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Low Serum Levels of Testosterone in Men with Minimal Traumatic Hip Fractures

E. Leifke1 , C. Wichers2 , V. Gorenoi1 , P. Lucke2 , A. von zur Mühlen1 , G. Brabant1
  • 1Devision of Gastroenterology, Hepatology and Endocrinology, MHH, Hannover, Germany
  • 2Geriatric Centre of Hagenhof Hospital, Hannover, Germany
Further Information

Publication History

Received: October 10, 2003 First decision: May 6, 2004

Accepted: March 4, 2005

Publication Date:
13 May 2005 (online)

Also available at
    Permissions and Reprints

Abstract

Sex steroids are essential for accretion and maintenance of bone mass. Their importance for osteoporotic fractures in men, however, are undefined. We determined circulating levels of testosterone (T), non-SHBG-bound T (bT), free testosterone (FT), oestradiol (E2), intact parathormone (iPTH), 25-OH-vitamin D (25(OH)D), and trabecular bone mineral density at spinal level (tBMD) by single quantitative computed tomography (QCT), respectively, in elderly men 1 - 3.5 months after minimal traumatic hip fractures (MTHF, age = 75 ± 10 ys, n = 27). A group of patients with non-immobilising stroke (S; age = 73 ± 8 ys, n = 12) served as controls. Men with known secondary osteoporosis were excluded from the study. Furthermore, serum levels of T and E2 were compared to healthy controls aged 20 - 30 years (n = 138) and 60 - 80 years (n = 110). In addition a literature-based analysis of studies on testosterone in men hip fractures were conducted. Mean tBMD of men with MTFH (52.7 ± 17.6 mg/cm3, T-score = - 4.5 ± 0.6) was significantly lower than in men with S (78 ± 16.3 mg/cm3, T-score = - 3.5 ± 0.8). Significant differences of the means between both groups were observed for T, bT, and FT but not for E2, 25(OH)D, and iPTH, respectively. About 90 % of men with MTHF had T serum levels 2 SD below the mean of young controls. This proportion reduced to 30 % if compared with serum levels of 60 - 80-year-old healthy men whereas men after S remained well within the normal range adjusted for age. Mean serum levels of iPTH were within the normal range (1 - 6.8 pmol/l); 25(OH)D serum levels were at the lower end of the normal control levels (30 - 190 nmol/l). There was an inverse relationship between iPTH and 25(OH)D (r = - 0,4; p < 0,03). In conclusion, low serum T is common in men with MTHF and only partly due to age. It appears to be a primary factor in fragility fractures in men and not simply secondary to morbidity following the fracture. In view of the scarce and inconsistent data published on this issue (1 longitudinal and 6 cross-sectional studies) the present study supports the patho-physiological relevance of low serum testosterone for the occurrence of MTHF in men.

Key words

(Minimal traumatic) hip fracture - male osteoporosis - testosterone - hypogonadism

References

  • 1 Behre H M, Kliesch S, Leifke E, Link T M, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.  Journal of Clinical Endocrinology and Metabolism. 1997;  82 2386-2390
    PubMedGoogle Scholar
  • 2 Behre H M, Yeung C H, Holstein A F, Weinbauer G F, Gassner P, Nieschlag E. Diagnosis of male infertility and hypogonadism. Nieschlag E, Behre HM Andrology: Male Reproductive Health and Dysfunction. 2nd ed. New York, Heidelberg, Berlin; Springer Verlag 2000: 90-140
    Google Scholar
  • 3 Boonen S, Vanderschhueren D, Cheng X G, Verbeke G, Dequeker J, Geusens P, Broos P, Bouillon R. Age-related (typeII) femoral neck osteoporosis in men: biochemical evidence for both hypovitaminosis D- and androgen deficiency-induced bone resorption.  J Bone Mineral Res. 1997;  12 2119-2126
    PubMedGoogle Scholar
  • 4 Center J R, Nguyen T V, Sambrook P N, Eisman J A. Hormonal and biochemical parameter and osteoporotic fractures in elderly men.  J Bone Mineral Res. 2000;  15 1405-1411
    PubMedGoogle Scholar
  • 5 Chapuy M C, Arlot M E, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas P D, Meunier P J. Vitamin D3 and calcium to prevent hip fractures in elderly women.  New Engl J Med. 1992;  327 1637-1642
    CrossrefPubMedGoogle Scholar
  • 6 Daniell H W. Narcotic-induced hypogonadism during therapy for heroin addiction.  J Addict Disorders. 2002;  21 47-53
    PubMedGoogle Scholar
  • 7 Diamond T, Smerdely P, Kormas N, Sekel R, Vu T, Day P. Hip fractures in elderly men: the importance of subclinical vitamin D deficiency and hypogonadism.  Med J Australia. 1998;  169 138-141
    PubMedGoogle Scholar
  • 8 Finkelstein J S. Androgens and bone metabolism. Nieschlag E, Behre HM Testosterone Action Deficiency Substitution. 2nd ed. Berlin, Heidelberg, New York; Springer Verlag 1998: 187-208
    Google Scholar
  • 9 Jackson J A, Riggs M W, Spiekermann A M. Testosterone deficiency as a risk factor to the occurence for hip fractures in men: a case control study.  Am J Med Sci. 1992;  304 4-8
    PubMedGoogle Scholar
  • 10 Kalender W A, Felsenberg D, Louis O, Lopez P, Klotz E, Osteaux M, Fraga J. Reference values for trabecular and cortical vertebral bone density in single and dual-energy quantitative computed tomography.  Eur J Radiol. 1989;  9 75-80
    PubMedGoogle Scholar
  • 11 Kaufmann J M, Vermeulen A. Androgens and senescence. Nieschlag E, Behre HM Testosterone Action Deficiency Substitution. 2nd ed. Heidelberg, Berlin, New York; Springer Verlag 1998: 437-472
    Google Scholar
  • 12 Kenny A M, Prestwood K M, Marcello K M, Raisz L G. Determinants of bone density in healthy older men with low testosterone level.  J Gerontol Medical Sciences. 2000;  55 M492-M497
    PubMedGoogle Scholar
  • 13 Kenny A M, Prestwood K M, Gruman C A, Marcello K M, Raisz L G. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels.  J Gerontol Medical Sciences. 2001;  56 A (5) M266-M272
    PubMedGoogle Scholar
  • 14 Kiebzak G M, Beinart G A, Perser K, Ambrose C G, Siff S J, Heggeness M H. Undertreatment of osteoporosis in men with hip fracture.  Archive Internal Medicine. 2002;  162 2217-2222
    PubMedGoogle Scholar
  • 15 Khosla S. The effects of androgens on osteoblast function in vitro.  Mayo Clinic Proceedings. 2000;  75 (Suppl) 51-54
    PubMedGoogle Scholar
  • 16 Khosla S. Oestrogen, bones and men: when testosterone just isn't enough.  Clin Endocrinol (Oxf). 2002;  56 291-293
    CrossrefPubMedGoogle Scholar
  • 17 Leifke E, Korner H C, Link T M, Behre H M, Peters P E, Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men.  Eur J Endocrinol. 1998;  138 51-58
    CrossrefPubMedGoogle Scholar
  • 18 Leifke E, Gorenoi V, Wichers C, von zur Mühlen A, von Büren E, Brabant G. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex hormone binding globulin levels in men: cross sectional data from a healthy male cohort.  Clin Endocrinol (Oxf). 2000;  53 689-695
    CrossrefPubMedGoogle Scholar
  • 19 Mawer E B, Davies M. Vitamin D nutrition and bone disease in adults.  Rev Endocrine Metab Disorders. 2001;  4 153-164
    PubMedGoogle Scholar
  • 20 Meikle A W. Androgen replacement therapy of male hypogonadism. Meikle AW Contemporary Endocrinology: Hormone Replacement Therapy. Totowa NJ; Humana Press Inc 1999: 263-306
    Google Scholar
  • 21 Mussolino M E, Looker A C, Madans J H, Langlois J A, Orwoll E S. Risk factors for hip fracture in white men: the NHANES I Epidemiologic Follow-up Study.  J Bone Mineral Res. 1998;  13 918-924
    PubMedGoogle Scholar
  • 22 Nyquist F, Gardsell P, Sernbo I, Jeppsson J O, Jonell O. Assessment of sex hormones and bone mineral density in relation to occurence of fracture in men: a prospective population based study.  Bone. 1998;  22 147-151
    CrossrefPubMedGoogle Scholar
  • 23 Ohishi T, Takahashi M, Kushida K, Omura T. Biochemical markers and bone mineral density in patients with hip fractures in men.  Endocrine Research. 2000;  26 275-288
    PubMedGoogle Scholar
  • 24 Poor G, Atkinson E J, O'Fallon W M, Melton J. Determinants of reduced survival following hip fractures in men.  Clin Orthop related Res. 1995;  319 260-265
    PubMedGoogle Scholar
  • 25 Orwoll E S, Klein R F. Osteoporosis in men.  Endocrine Rev. 1995;  16 87-144
    CrossrefPubMedGoogle Scholar
  • 26 Orwoll E S. Androgens: basic biology and clinical implication.  Calcified Tissue International. 2001;  69 185-188
    CrossrefPubMedGoogle Scholar
  • 27 Orwoll E S, Stribrska L, Ramsey E E, Keenan E J. Androgen receptors in osteoblast-like cell lines.  Calcified Tissue International. 1991;  49 183-187
    PubMedGoogle Scholar
  • 28 Pfeifer M, Begerow B, Minne H W, Jensen S B, Christiansen C. Effect of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women.  J Bone Mineral Res. 2000;  15 1113-1118
    CrossrefPubMedGoogle Scholar
  • 29 Quesada J M, Coopmans W, Ruiz B, Aljama P, Jans I, Bouillon R. Influence of vitamin D on parathyroid function in elderly.  J Clin Endocrinol Metab. 1992;  75 494-501
    CrossrefPubMedGoogle Scholar
  • 30 Seeman E. Unresolved issues in osteoporosis in men.  Rev Endocrine Metab Disorders. 2001;  2 45-64
    CrossrefPubMedGoogle Scholar
  • 31 Seeman E. The dilemma of osteoporosis in men.  Am J Med. 1995;  98 76-88
    PubMedGoogle Scholar
  • 32 Shozu M, Simpson E R. Aromatase expression of human osteoblast-like cells.  Mol Cell Endocrinol. 1998;  139 117-129
    CrossrefPubMedGoogle Scholar
  • 33 Snyder P J, Peachey H, Hannoush P, Berlin J A, Loh L, Holmes J H, Dlewati A, Staley J, Santanna J, Kapoor S C, Attie M F, Haddad Jr J G, Strom B L. Effect of testosterone treatment on bone mineral density in men over 65 years of age.  J Clin Endocrinol Metab. 1999;  84 1966-1972
    CrossrefPubMedGoogle Scholar
  • 34 Stanley H L, Schmitt B P, Poses R M, Deiss W P. Does hypogonadism contribute to the occurence of minimal trauma hip fracture in elderly men?.  J Am Geriatrics Society. 1991;  39 766-771
    PubMedGoogle Scholar
  • 35 Trombetti A, Hermman F, Hoffmeyer P, Schurch M A, Bonzour J P, Rizzoli R. Survival and potential years of life lost after hip fracture in men and age-matched women.  Osteoporosis Int. 2002;  13 731-737
    CrossrefPubMedGoogle Scholar
  • 36 Van den Berghe G. Dynamic neuroendocrine responses to critical illness.  Front Neuroendocrinology. 2002;  23 370-391
    PubMedGoogle Scholar
  • 37 Wang C, Chan V, Yeung R TT. Effect of surgical stress on pituitary-testicular function.  Clin Endocrinol (Oxf). 1978;  9 249-253
    CrossrefPubMedGoogle Scholar
  • 38 Wang C, Swerdloff R S, Iranmanesh A, Dobs A, Snyder P J, Cunnigham G, Matsumoto A M, Weber T, Berman N. and the Testosterone Gel Study Group . Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.  Clin Endocrinol (Oxf). 2001;  54 739-750
    CrossrefPubMedGoogle Scholar
  • 39 Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto A M, Snyder P J, Weber T, Berman N, Hull L, Swerdloff R. Long-term testsosterone gel (Androgel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.  J Clin Endocrinol Metab. 2004;  89 2085-2098
    CrossrefPubMedGoogle Scholar
  • 40 Zitzmann M, Brune M, Kornmann B, Gromoll J, Junker R, Nieschlag E. The CAG repeat poymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males.  Clin Endocrinol (Oxf). 2001;  55 649-657
    CrossrefPubMedGoogle Scholar

MD Eckhard Leifke

Clinical Development G and A Schering AG

Sellerstr. 31

13347 Berlin

Germany

Phone: + 49(0)30468192222

Fax: + 49 (0) 3 04 68 99 22 22

Email: eckhard.leifke@schering.de

      >